Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

Biomarin

BioMarin’s application for haemophilia A gene therapy accepted by FDA

If approved, the treatment would be the first gene therapy in the US for this indication

- PMLiVE

Seeing AI app launched by Haleon and Microsoft to enhance sight accessibility

The app is free to download from the Apple App Store and will be available on Android in the future

Beyond Knowledge Transfer: Generating Actionable Insights for Medical Affairs

Presented at Evidence Life Science’s Medical Affairs Digital Conference March 9, 2021. Presenters: Christina L. Hoffman, MS, Global Lead for Medscape Medical Affairs Gökhan Tanju, Executive Director, Business Intelligence for...

Medscape Medical Affairs

Actionable Insights for Medical Affairs Teams: Lessons from the Front Lines

Presented at Fierce Pharma’s Medical Affairs Launch Excellence Conference February 4, 2021. With Christina L. Hoffman, MS, Global Lead for Medscape Medical Affairs. Chris speaks to two primary remits: Knowledge...

Medscape Medical Affairs

Patient Centric Approaches for Rare and Ultra-Rare Diseases

Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale....

Impetus Digital

Bedrock new starters

Bedrock expands growing strategy and scientific teams

Award-winning Bedrock Healthcare Communications adds three new starters at an exciting time of growth. Meet our new faces and find out what drew them to Bedrock.

Bedrock Healthcare Communications

- PMLiVE

The impact of war on patients and clinical research

By Thomas Dobmeyer

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes

Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster approved for emergency use by FDA in children five to 11 years

The doses will be shipped immediately, pending recommendation from the CDC

- PMLiVE

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

The study enrolled the ‘broadest and most diverse’ patient population ever studied in an SMA trial

regeneron headquarters

Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review

The rare eye disease often impacts infants who are born before 31 weeks of pregnancy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links